More on CMMB

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-100.0% Growth)
- Ratings (10.0 Score)

Upcoming Events

- Earnings (3/3/26 *Est.)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Chemomab Therapeutics (NQ:CMMB)
Delayed: 1.88 +0.05 (2.73%)
Prev. Close $1.83  
Open$1.91 
52 Wk High$ 
52 Wk Low$ 
Day High$1.91 
Day Low$1.77 
P/E N/A  
EPS$ 
Volume51,558 


Feb 17, 2026 04:49 PM Form SCHEDULE 13G/A Chemomab Therapeutics Filed by: THIEL PETER
Feb 17, 2026 08:00 AM Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
Feb 10, 2026 04:43 PM Form SCHEDULE 13G/A Chemomab Therapeutics Filed by: Otto Erik
Dec 2, 2025 08:01 AM Chemomab publishes phase 2 PSC trial results in medical journal
Dec 2, 2025 08:00 AM Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology
Nov 24, 2025 08:00 AM Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
Nov 21, 2025 06:16 AM Form 6-K Chemomab Therapeutics For: Nov 21
Nov 20, 2025 08:00 AM Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Nov 6, 2025 08:00 AM Chemomab to present PSC drug trial data at liver conference
Nov 6, 2025 08:00 AM Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis
View All Articles

Entities mentioned with CMMB

View All Entities